Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Eleftherios P. Mamounas; Hanna Bandos; Priya Rastogi; Yi Zhang; Kai Treuner; Peter C. Lucas; Charles E. Geyer; Louis Fehrenbacher; Stephen Chia; Adam Brufsky; Janice M. Walshe; Gamini S. Soori; Shaker R. Dakhil; Soonmyung Paik; Sandra M. Swain; Dennis C. Sgroi; Catherine A. Schnabel; Norman Wolmark

doi:10.1158/1078-0432.25728529.v1

May 1, 2024Open Access

Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

Primary cancer development was compared between extended letrozole and placebo regimens within the translational Breast Cancer Index NSABP B-42 cohort.
Exploratory Kaplan-Meier analysis evaluated rates of any new primary cancer alongside new breast primary cancer between extended letrozole and placebo groups.
Findings support evaluating the Breast Cancer Index to clarify long-term benefit from extended aromatase inhibitor therapy in hormone receptor-positive disease.

Implication

Randomized trial exploratory analysis shows new primary cancer incidence under extended letrozole in hormone receptor-positive breast cancer, highlighting Breast Cancer Index utility.

Abstract

Supplemental Figure SF2. Exploratory Kaplan-Meier analysis based on A, any new primary cancer and B, new breast primary cancer comparing extended letrozole vs placebo in the overall Breast Cancer Index (BCI) NSABP B-42 translational cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mamounas et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db6435876434d2 https://doi.org/10.1158/1078-0432.25728529.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers